VIO Med Spa Clifton
VIO Med Spa Clifton · 345 Allwood Road · Clifton, NJ 07012
5.0· 459 Google reviews
Listing updated October 2, 2026
No current plans confirmed — RetaMaps has not yet confirmed this practice's intentions regarding retatrutide. Inclusion on RetaMaps does not mean the provider offers or will offer retatrutide.
Care described on the practice's website
- Medically supervised weight loss
About this practice
Clifton, New Jersey is home to VIO Med Spa Clifton, a medical spa that, per its website, offers injectables, skin treatments, body contouring and wellness services and works under the clinical direction of a board-certified plastic surgeon. Its Google profile shows a 5.0-star rating across 459 reviews that start in 2025, with 97 in the past year. Reviewers talk most about the providers' knowledge and the staff, and 13 mention results. The listing also includes weight-loss and hormone care.
Services & access
| Advertises semaglutide today | Not listed |
| Advertises tirzepatide today | Not listed |
| Telehealth visits | Not listed |
| Cash pay accepted | — |
| Accepts insurance — per practice website | Yes |
| Accepting new patients — per practice website | Yes |
"Not listed" means we didn't find this stated on the practice's public pages — it doesn't mean no. — means unknown. Medication rows describe currently FDA-approved GLP-1 medications the practice advertises today, not retatrutide. Confirm details directly with the practice.
Review activity
Counts computed by RetaMaps from public Google reviews; most recent review 2026-09-29. Read the reviews themselves on the practice's Google listing.
What patients say
Rated ★5.0 across 459 Google reviews. Of the 100 reviews we analyzed, 100 (100%) are positive (4–5★) and 0 (0%) are negative (1–2★).
What patients like
- Knowledgeable, professional providers35 reviews
- Friendly, helpful staff31 reviews
- Weight-loss results13 reviews
- Clean, comfortable office11 reviews
Common complaints
No negative reviews among those we analyzed.
Most recent Google reviews
Doriana M.★★★★★2026-09-29I had such a wonderful HydraFacial today! Shaya was exceptional from start to finish. She took her time, made me feel comfortable, and gave my skin the attention it needed. I left with my face feeling clean, hydrated, and glowing. She also gave me her signature massage, which is always one of my favorite parts of the visit. After a long, busy day at work, it was exactly what I needed. I left feeling relaxed, refreshed, and truly cared for. I’m already looking forward to my next appointment!
Cynthia L.★★★★★2026-09-28NP Christina is amazing for my masseter muscle injections for clenching! Very thoughtful for my concerns and reasonable with the amounts of Daxify used towards my jaw. Pretty small injections and little to none pain (I'm a big baby with pain*).
Michael L.★★★★★2026-09-26What a wonderful experience! And the results?! 🔥🔥 thanks Betsy!
Adrianna G.★★★★★2026-09-25Highly recommend Shaya for all your facial needs! She is gentle, professional and knowledgeable. Look forward to coming back again!
Anthony K.★★★★★2026-09-09Juliana was amazing! I saw her for my daxxify treatment while I was in town and she was personable, did a great job and was fast and efficient. Nathalie the manager is great and the entire experience was awesome from start to finish. 10/10 recommend!
Analysis by RetaMaps of reviews on this practice's public Google Business listing; review themes are detected automatically and reviews reflect their authors' opinions. See all reviews on Google.
Nearby providers in Clifton
JeLuJa Medspa and Weight loss at Clifton
1033 U.S. 46 · Clifton, NJ 07013
4.7(51 Google reviews · 2 in past year)
Retatrutide is Eli Lilly's investigational once-weekly triple agonist (GIP, GLP-1 and glucagon receptors). Five Phase 3 trials have reported positive results, and Lilly plans to submit it to the FDA in Q1 2027. It is not FDA-approved, has no brand name or price, and cannot be prescribed outside clinical trials or Lilly's physician-requested expanded access program. Products sold online as "research" or compounded retatrutide are not legitimate retatrutide.
- Development
- Phase 3 complete
- FDA status
- Submission planned — Q1 2027 (Lilly guidance)
- Availability
- Not commercially available
- Access routes
- Clinical trials, or Lilly's expanded access program (physician must apply)
Next milestone: TRIUMPH-5 head-to-head vs tirzepatide results (Expected ~Dec 2026)
Sources: Lilly — What to know about retatrutide · Lilly — TRIUMPH-2/TRIUMPH-3 results · BioPharma Dive — FDA submission plans · STAT — Lilly expanded access (Aug 3, 2026) · FDA — Concerns with unapproved GLP-1 drugs